

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

DR. GERALD LAURENCE MURRAY (Orcid ID : 0000-0003-3330-4433)

Article type : Original Article

The impact of sample storage on molecular-based detection of *Mycoplasma genitalium*

Gerald L. Murray,^{1,2,3} Jenny P. Su,² Josh Birnie,² Jennifer Danielewski,^{1,2} Dorothy A. Machalek,^{1,2,4}
Catriona S. Bradshaw,^{4,5,6} Tim R. H. Read,^{5,6} Anna-Maria Costa,^{1,7} Suzanne M Garland^{1,2,8}

¹ Centre for Women's Infectious Diseases, The Royal Women's Hospital, Park Parkville VIC 3052

² Molecular Microbiology Research Group, Murdoch Children's Research Institute, Parkville VIC 3052

³ Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, VIC 3800

⁴ Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, VIC 3052

⁵ Melbourne Sexual Health Centre, Alfred Health, Carlton, VIC 3053

⁶ Central Clinical School, Monash University, Melbourne, VIC 3004

⁷ The Royal Children's Hospital, Parkville, VIC 3052

⁸ Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC 3052

Running title: Impact of storage on *M. genitalium* detection

Correspondence: Gerald L. Murray, email: Gerald.murray@mcri.edu.au; phone: +613 8345 3679

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/JAM.14359](https://doi.org/10.1111/JAM.14359)

This article is protected by copyright. All rights reserved

27 Aims. *Mycoplasma genitalium* causes a common, sexually-transmitted bacterial infection. This
28 study assessed the detection of *M. genitalium* in stored urine samples to understand the impact of
29 sample storage on *M. genitalium* detection.

30 Methods. Aliquots of *M. genitalium*-positive urine (n=20 patients) were stored at either room
31 temperature (22°C) or 4°C, without a preservative. At weekly intervals samples were tested using
32 the commercial test ResistancePlus MG® (SpeedX®, Australia). We report the analysis at 1 week,
33 an acceptable collection-to-test turnaround time, with further analysis over 5 weeks to illustrate
34 degradation trends.

35 Results. After storage at 4°C, the proportion of specimens that remained positive for *M.*
36 *genitalium* was 100% after 1 week and 95% after 4 weeks. Storage at 22°C led to more rapid
37 decline in detection in the first 4 weeks, with 95% detected after 1 week and 85% at two weeks
38 onwards. At 5 weeks, samples stored at both temperatures had an 85% *M. genitalium* detection
39 rate, with increase in crossing points (ΔCq) of 0.72 (95% confidence interval [CI] 0.01–1.43; p-
40 trend=0.027) at 4°C, and 1.75 ([95%CI 0.79-2.71], p-trend <0.001) at 22°C.

41 Conclusions. Urine samples stored without preservative, and unfrozen, retained high *M.*
42 *genitalium* detection levels over the short term (up to 5 weeks). To minimise degradation storage
43 at 4°C is recommended.

44 Significance and Impact. There is little known about the stability of clinical samples for *M.*
45 *genitalium* detection. This study found a high proportion (85-100%) of samples are still suitable for
46 *M. genitalium* detection after storage for up to 5 weeks.”

47
48 **Keywords:** Diagnosis; PCR; Molecular genetic; Degradation; Detection

49 Introduction

50 *Mycoplasma genitalium* is a sexually-transmitted bacterium that causes urethritis in men (Horner et
51 al., 2017). In women, infection has been associated with cervicitis, endometritis, and elevates the
52 risk of tubular factor infertility and pregnancy complications (Lis et al., 2015). There is a high
53 infection burden in some populations such as men-who-have-sex-with-men (MSM) where
54 asymptomatic colonisation rates are as high as 9.5% (Read et al., 2019). There has also been a
55 dramatic increase in resistance to antimicrobial therapies, with resistance to the first-line treatment
56 (azithromycin) as high as 84% in MSM populations in Australia (Read et al., 2019). Together this
57 has highlighted an increased need for diagnostic testing and research to further understand this
58 infection. Both diagnostics and research have been advanced by the release of commercial nucleic
59 acid amplification tests for *M. genitalium* (Tabrizi et al., 2016, Tabrizi et al., 2017).

60

61 With the increase in *M. genitalium* testing, it is important to understand the impact that delays in
62 sample processing may have on *M. genitalium* detection, for which there is currently no
63 information. Urine is a commonly recommended specimen for testing *M. genitalium* infection
64 (Jensen et al., 2016). In this study, urine samples were stored *in vitro* at two temperatures (room
65 temperature and 4°C), to assess the effect on *M. genitalium* detection by a commercial assay over a
66 5-week period.

67

68 **Materials and Methods**

69 **Data extraction for sample collection-to-test times**

70 The time between sample collection and testing for *M. genitalium* was examined for a metropolitan
71 testing laboratory, Melbourne, Australia. The period studied was January to May 2018.

72

73 **Sample selection from existing clinical studies**

74 First-void urine samples were collected from men attending Melbourne Sexual Health Centre
75 between the 7th of February 2017 until the 31st May 2017 as part of ongoing clinical study (Read et
76 al., 2019). Samples were delivered to the Royal Women's Hospital at 4°C for *M. genitalium* testing
77 (median delivery time of 1 day), DNA was extracted from 1mL of urine as described previously
78 (Read et al., 2018) and 5 µL of extract tested for *M. genitalium* using the ResistancePlus MG test
79 (SpeeDx, Australia)(Tabrizi et al., 2017). For the purpose of this study, 20 sequential positive
80 samples with a ≥10 mL residual volume were selected. The samples used in this study were
81 collected under ethics approval from the Alfred Hospital Ethics Committee (289/17).

82

83 **Sample processing for sample stability analysis**

84 The processing of samples is outlined in Figure 1. Urine samples were vortex-mixed, turbidity
85 noted by eye (non-standardised method, either “turbid” or “not turbid”), then ten 1 mL aliquots
86 transferred to sterile 1.5 mL polypropylene screw-capped tubes (Sarstedt, Germany). Aliquots were
87 stored in the dark, at either room temperature (approx. 22°C, in a cupboard in an air-conditioned
88 room with limited temperature variation) or 4°C. At one-week intervals for 5 weeks, an aliquot of
89 each sample was taken and extracted as above, then stored at -30°C (for up to 6 months) before
90 batch testing for *M. genitalium*, as described above (week 1 to week 5). Cycle threshold (Cq) values
91 were determined for samples based on detection of the MGPA gene (channel A, FAM), with an

92 increase in Cq value indicative of sample degradation. The distribution of initial Cq values for
93 samples was: Cq<20, 2 samples; Cq=20-24, 9 samples; Cq=25-29, 6 samples; Cq=30-35, 3
94 samples. A subset of samples (the first 14 samples collected) was also analysed for β -globin
95 detection by quantitative PCR, as described previously (Cornall et al., 2013). Culture analysis of
96 urine samples was not performed.

97

98 **Data analysis**

99 Tests that had no detectable analyte were assigned an arbitrary Cq value at the limit of detection
100 (Cq=35 for *M. genitalium* detection, Cq=40 for β -globin detection). The change in Cq values was
101 analysed for difference by Student's t-test and for trend by fixed effects regression analysis using
102 STATA (v14.2, StataCorp LLC).

103

104

105

106 **Results**

107 **Sample collection-to-test times can exceed 2 weeks**

108 Collection-to-test times were analysed for a diagnostic laboratory over a period of 5 months. For
109 3623 *M. genitalium* tests, 96.6% of samples were tested within one week of collection, 3.1%
110 (n=114) one to two weeks after collection, and 0.25% (n=9) more than two weeks after collection.
111 The oldest sample for this period was tested 44 days after collection. Of note, these collection-test
112 times reflect delays in the sample reaching the laboratory, not delays in the testing laboratory (only
113 one sample in this period had a laboratory turn-around-time of more than 7 days). Anecdotally,
114 clinics blamed delays on sample misplacement and misdirection. This illustrates that prolonged
115 collection-test times are common as a result of delays in sample delivery to the pathology
116 laboratory, and consideration should be given to the impact this has on false negative results. In the
117 following sections we analysed the impact of sample storage for 1 week (an acceptable collection-
118 to-test turnaround time), then for an additional 4 weeks to establish stability trends.

119

120 **Detection of *M. genitalium* in urine specimens remains high after several weeks of storage**

121 Samples had an average starting Cq value of 24.4 (range: 17.7 to 33.0). After storage at 4°C, the
122 level of detection of *M. genitalium* was: week 1, 100% positive; weeks 2-4, 95% positive; week 5,
123 85% positive (Figure 2). Storage at 22°C led to an earlier decline in detection: week 1, 95%
124 positive; weeks 2-5, 85% positive. The mean increase in Cq value over 5 weeks at 4°C was 0.72
125 (95% confidence interval [CI] 0.01–1.43; p-trend = 0.027) and at 22°C it was 1.75 (95%CI 0.79-
126 2.71; p-trend <0.001). The change in Cq value at 22°C was not significantly different to that at 4°C
127 (p=0.20, Student's t-test).

128

129 Samples that crossed beyond the threshold of *M. genitalium* detection had higher starting Cq values
130 (mean 29.1, compared with 22.8; p=0.0032). Only one individual had samples testing negative after
131 storage in both conditions at 5 weeks.

132

133 **Human DNA degradation at both temperatures**

134 Human DNA stability was assessed by quantitative PCR targeting a 110 bp region of the β -
135 globin gene. The amplicon size for this assay is similar to that in the ResistancePlus MG test
136 (approximately 120 bp). While detection rates for β -globin were generally higher, there was a
137 stronger trend and magnitude for increasing Cq values, indicative of sample degradation; over 5
138 weeks at 4°C there was a Δ Cq of 1.82 (95%CI 1.11-2.54), p-trend <0.001, and over 5 weeks at 22°C
139 there was a Δ Cq of 3.00 (95%CI 2.13-3.86), p-trend <0.001 (Figure 2). However, when compared
140 to the change in Cq values for *M. genitalium* detection, the change in Cq values for β -globin
141 detection over 5 weeks was not significantly different (p \geq 0.16).

142

143 **Sample turbidity did not impact *M. genitalium* detection**

144 Urine turbidity was used as an indicator for bacterial contamination of samples. Twenty-five
145 percent (5/20) samples had observable turbidity at the start of the experiment, and all turbid samples
146 tested positive for *M. genitalium* throughout the experiment.

147

148 **Discussion**

149 Delays in testing samples at pathology clinics or research laboratories may occur as a result of
150 multiple factors, including transport, sample processing, and human error. For research studies such

151 as surveillance, sampling may take place in remote locations necessitating sample transport to the
152 laboratory. The effect of delays on sample integrity for the detection of *M. genitalium* by nucleic
153 acid amplification methods is not well characterised. We found that the rate of *M. genitalium*
154 detection in positive urine samples remained high, despite incubation at room temperature or 4°C
155 for 5 weeks. While storage at 4°C appeared to result in superior preservation of bacterial DNA
156 compared to storage at room temperature, this did not reach statistical significance. Samples that
157 became “undetectable” generally had lower *M. genitalium* DNA content at the outset, reflected in
158 higher starting Cq values. Additionally, samples with lower concentration of analyte showed greater
159 variation in Cq values; this may be a consequence of errors introduced during the preparation of the
160 samples (e.g. stochastic sampling error, loss of sample during removal of supernatant from pellets,
161 incomplete resuspension of samples in PBS). The growth of other bacteria in the sample (e.g. from
162 a urinary tract infection) may accelerate degradation of the sample; however, in this study visible
163 turbidity of the urine sample did not impact the detection of *M. genitalium*. Of note, however,
164 turbidity may also result from the presence of immune cells.

165

166 There has been very little work analysing the stability of primary clinical samples for *M. genitalium*
167 detection. A study investigating the effect of transport of urine samples found that neat urine and
168 urine adsorbed to swabs (n=5 patients) retained detectable *M. genitalium* by an in-house qPCR
169 assay 10 days after incubation at 37°C, without use of a transport/stabilisation buffer (Costa et al.,
170 2017). Another study on sample integrity found that freezing primary urine samples at -20°C
171 reduces the detection rate for *M. genitalium*, yielding a 9% false negative rate (Carlsen et al., 2010)
172 (of note this study used a smaller 78 bp amplicon, compared to the 120 bp amplicon of the
173 ResistancePlus MG assay). While our study used a smaller number of samples, results suggest that
174 storage of neat urine at 4°C over the short term (0-4 weeks) would preserve samples better than
175 freezing.

176

177 The analysis of only one sample type (urine) collected from male participants is a limitation of this
178 study, meaning results may not be generalizable to women or other sample types. Including two
179 temperatures and the longer incubation period are the strengths of the study.

180

181 In conclusion, this study shows that samples remain “detectable” for *M. genitalium* after significant
182 periods of storage. While clinical specimens should be tested in the shortest time possible in
183 accordance with good laboratory practice, for short term storage (1-4 weeks) 4°C is preferable to

184 room temperature. More work is needed to determine optimum storage conditions for longer
185 periods.

186

187 **Acknowledgements**

188 We acknowledge the support of SpeedX in providing the detection kits for the assays. This work
189 was supported by an Innovations Connections grant from the Department of Industry, Innovation
190 and Science, The Australian Federal Government (grant number ICG000220). T.R.H.R. was
191 supported by early career fellowship number 1091536 from the National Health and Medical
192 Research Council.

193

194 **Conflict of Interest**

195 The authors have jointly received Government funding with SpeedX to conduct this work, and
196 SpeedX provided detection kits for the assays.

197

198 Carlsen, K. H. & Jensen, J. S. (2010) *Mycoplasma genitalium* PCR: does freezing of specimens
199 affect sensitivity? *J Clin Microbiol*, **48**, 3624-7.

200 Cornall, A. M., Roberts, J. M., Garland, S. M., Hillman, R. J., Grulich, A. E. & Tabrizi, S. N.
201 (2013) Anal and perianal squamous carcinomas and high-grade intraepithelial lesions
202 exclusively associated with "low-risk" HPV genotypes 6 and 11. *Int J Cancer*, **133**, 2253-8.

203 Costa, A. G., Garland, S. M., Guy, R., Wand, H. & Tabrizi, S. N. (2017) UriSwab: an effective
204 transport medium for nucleic acid detection of *Chlamydia trachomatis*, *Mycoplasma*
205 *genitalium* and *Neisseria gonorrhoeae*. *Sex Health*, **14**, 502-506.

206 Horner, P. J. & Martin, D. H. (2017) *Mycoplasma genitalium* infection in Men. *J Infect Dis*, **216**,
207 S396-S405.

208 Jensen, J. S., Cusini, M., Gomberg, M. & Moi, H. (2016) 2016 European guideline on *Mycoplasma*
209 *genitalium* infections. *J Eur Acad Dermatol Venereol*, **30**, 1650-1656.

210 Lis, R., Rowhani-Rahbar, A. & Manhart, L. E. (2015) *Mycoplasma genitalium* infection and female
211 reproductive tract disease: a meta-analysis. *Clin Infect Dis*, **61**, 418-26.

212 Read, T. R. H., Jensen, J. S., Fairley, C. K., Grant, M., Danielewski, J. A., Su, J., Murray, G. L.,
213 Chow, E. P. F., Worthington, K., Garland, S. M., Tabrizi, S. N. & Bradshaw, C. S. (2018)
214 Use of pristinamycin for macrolide-resistant *Mycoplasma genitalium* Infection. *Emerg Infect*
215 *Dis*, **24**, 328-335.

216 Read, T. R. H., Murray, G. L., Danielewski, J., Fairley, C. K., Doyle, M., Worthington, K., Su, J.
217 P., Mokany, E., Tan, L. T., Lee, D., Vodstrcil, L. A., Chow, E. P. F., Garland, S. M., Chen,

218 M. Y. & Bradshaw, C. S. (2019) Symptoms, sites and significance: *Mycoplasma genitalium*
219 in men who have sex with men. *Emerg Infect Dis*, **25**, DOI: 10.3201/eid2504.181258.
220 Tabrizi, S. N., Costa, A. M., Su, J., Lowe, P., Bradshaw, C. S., Fairley, C. K. & Garland, S. M.
221 (2016) Evaluation of the Hologic Panther transcription-mediated amplification assay for
222 detection of *Mycoplasma genitalium*. *J Clin Microbiol*, **54**, 2201-3.
223 Tabrizi, S. N., Su, J., Bradshaw, C. S., Fairley, C. K., Walker, S., Tan, L. Y., Mokany, E. &
224 Garland, S. M. (2017) Prospective evaluation of ResistancePlus MG, a new multiplex qPCR
225 assay for the detection of *Mycoplasma genitalium* and macrolide resistance. *J Clin*
226 *Microbiol*, **55**, 1915-1919.

227

228

229

230

231

232

233 **Fig. 1.** Sample processing procedure.

234

235

236 **Fig. 2.** Detection of analytes after sample storage at two different temperatures. (a) *M. genitalium*
237 detection, storage at 4°C; (b) *M. genitalium* detection, storage at 22°C; (c) β -globin detection,
238 storage at 4°C; (d) β -globin detection, storage at 22°C. (○) Percent detection in samples (left axis);
239 (●) mean change in Cq values (right axis). Error bars indicate 95% confidence intervals, p-trend for
240 Δ Cq was 0.027 (panel A) and <0.001 (panels B-D).



